Upcoming Login Downtime

We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.

For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
ARTICLE | Clinical News

Numax: Phase I/II data

May 23, 2005 7:00 AM UTC

Data from a dose-escalation, North and South American Phase I/II trial in 217 preterm infants and infants with chronic lung disease showed that Numax was safe and well tolerated. Each infant received ...